Isotyping immunoglobulins using accurate molecular mass

Patent metadata

Field	Value
Publication number	US-10753945-B2
Application number	US-201916297340-A
Country	US
Kind code	B2
Filing date	Mar 8, 2019
Priority date	Apr 4, 2014
Publication date	Aug 25, 2020
Grant date	Aug 25, 2020

Abstract

This document relates to methods for detecting and quantifying heavy and light chains of immunoglobulin using mass spectrometry techniques.

First claim

What is claimed is:

1. A method for detecting immunoglobulin heavy chains in a sample, the method comprising:
a) providing a biological sample comprising immunoglobulins, paired immunoglobulin heavy and light chains, or mixtures thereof;
b) immunopurifying the sample, wherein the immunopurifying comprises using an antibody selected from the group consisting of an anti-human IgG antibody, an anti-human IgA antibody, an anti-human IgM antibody, an anti-human IgD antibody, an anti-human IgE antibody, and combinations thereof;
c) subjecting the immunopurified sample to a decoupling step wherein immunoglobulin light chains are decoupled from immunoglobulin heavy chains; and
d) subjecting the decoupled sample to a mass spectrometry technique to obtain a mass spectrum of the sample, said mass spectrum comprising one or more peaks corresponding to one or more intact immunoglobulin heavy chains in the sample; wherein said one or more peaks quantify the amount of the one or more intact immunoglobulin heavy chains in the sample.

2. The method of claim 1 , wherein the antibody is a non-human antibody.

3. The method of claim 2 , wherein the non-human antibody is at least one of a camelid antibody, a cartilaginous fish antibody, llama, sheep, goat, or a mouse antibody.

4. The method of claim 3 , wherein the antibody is a single domain antibody fragment (SDAF).

5. The method of claim 4 , wherein the SDAF is derived from a camelid antibody, a cartilaginous fish antibody, llama, a mouse antibody, sheep, goat, or a human antibody.

6. The method of claim 5 , wherein the SDAF is selected such that the mass spectrum generated in step c) for the single domain antibody fragment does not overlap with the mass spectrum generated in step c) for the immunoglobulin light chain or immunoglobulin heavy chain.

7. The method of claim 6 , wherein the SDAF is selected such that the SDAF generates a signal of about 12,500 to about 15,000 m/z in step c) with a single charge.

8. The method of claim 1 , wherein the sample comprising immunoglobulin light chains, immunoglobulin heavy chains, or mixtures thereof is analyzed as a single fraction in a single analysis.

9. The method claim 1 , further comprising determining the pairing of immunoglobulin heavy chains and immunoglobulin light chains in the sample.

10. The method of claim 1 , further comprising determining the quantitative amount of one or more of the immunoglobulin heavy chains in the sample.

11. The method claim 1 , further comprising identifying a M-protein in the sample.

12. The method of claim 11 , further comprising quantifying the M-protein in the sample.

13. The method of claim 12 , further comprising determining the pairing of immunoglobulin heavy chains and immunoglobulin light chains in the M-protein in the sample.

14. A method for detecting immunoglobulin heavy chains in a sample, the method comprising:
a) providing a biological sample comprising immunoglobulins, paired immunoglobulin heavy and light chains, or mixtures thereof,
b) immunopurifying the sample utilizing a single domain antibody fragment (SDAF) having affinity for an immunoglobulin, wherein said SDAF is selected from the group consisting of an anti-human IgG SDAF, an anti-human IgA SDAF, an anti-human IgM SDAF, an anti-human IgD SDAF, an anti-human IgE SDAF, an anti-human kappa SDAF, an anti-human lambda SDAF, and combinations thereof;
c) subjecting the immunopurified sample to a decoupling step where light chain immunoglobulins are decoupled from the heavy chain immunoglobulins;
wherein one or more of the immunoglobulin light chains or immunoglobulin heavy chains is derived from an M-protein;
d) subjecting the immunopurified sample to a mass spectrometry technique to obtain a mass spectrum of the sample, said mass spectrum comprising one or more peaks corresponding to one or more intact immunoglobulin light chains in the sample; wherein said one or more peaks quantify the amount of the one or more intact immunoglobulin heavy chains in the sample,
wherein the mass spectrometry technique is chosen from the group consisting of (i) liquid chromatography electrospray ionization coupled to mass analyzer (ii) a microflow liquid chromatography electrospray ionization coupled to a quadrupole time-of-flight mass spectrometry technique and (iii) a matrix assisted laser adsorption ionization-time of flight mass spectrometry technique; and
e) determining one or more of (i) the identity of the M-protein, (ii) the quantity of the M-protein, (iii) the pairing of immunoglobulin heavy chains and immunoglobulin light chains of the M-protein, and (iv) the quantitative amount of one or more of the immunoglobulin heavy chains and M-protein in the sample.

15. The method of claim 14 , wherein the SDAF is derived from a camelid antibody, a cartilaginous fish antibody, llama, a mouse antibody, sheep, goat, or a human antibody.

16. The method of claim 15 , wherein the SDAF is selected such that the mass spectrum generated in step d) for the SDAF does not overlap with the mass spectrum generated in step d) for the immunoglobulin light chain or immunoglobulin heavy chain.

17. The method of claim 16 , wherein the SDAF is selected such that the SDAF generates a signal of about 12,500 to about 15,000 m/z in step d) with a single charge.

18. A method for monitoring treatment of a disorder in a subject, said method comprising:
a) providing a biological sample obtained from the subject, wherein the biological sample comprises immunoglobulins, paired immunoglobulin heavy and light chains, or mixtures thereof;
b) immunopurifying the sample, wherein the immunopurifying comprises using an antibody selected from the group consisting of an anti-human IgG antibody, an anti-human IgA antibody, an anti-human IgM antibody, an anti-human IgD antibody, an anti-human IgE antibody, and combinations thereof;
c) subjecting the immunopurified sample to a decoupling step wherein immunoglobulin light chains are decoupled from immunoglobulin heavy chains; and
d) subjecting the decoupled sample to a mass spectrometry technique to obtain a mass spectrum of the sample, said mass spectrum comprising one or more peaks corresponding to one or more intact immunoglobulin heavy chains or one or more intact immunoglobulin light chains in the sample; wherein said one or more peaks quantify the amount of the one or more intact immunoglobulin heavy chains or one or more intact immunoglobulin light chains in the sample.

19. The method of claim 18 , wherein the treatment comprises administering a therapeutic monoclonal antibody to the subject, and wherein said one or more peaks that quantify the amount of the one or more intact immunoglobulin heavy chains or one or more intact immunoglobulin light chains are from said therapeutic monoclonal antibody.

20. The method of claim 18 , wherein said biological sample is selected from the group consisting of a whole blood sample, a serum sample, a plasma sample, a urine sample, and a cerebrospinal fluid sample.

Assignees

• Mayo Found Medical Education & Res

Inventors

• Murray David L
• Barnidge David R
• Dasari Surendra
• Mills John R

Classifications

• G01N33/6848 Primary

  Methods of protein analysis involving mass spectrometry · CPC title

• G01N30/7266

  by electric field, e.g. electrospray · CPC title

• G01N2800/52

  Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis · CPC title

• G01N33/6857

  Antibody fragments · CPC title

• G01N2800/7095

  Inflammation · CPC title